Compare CURX & PLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURX | PLSM |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Israel |
| Employees | 6 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 11.6M |
| IPO Year | 2024 | 2025 |
| Metric | CURX | PLSM |
|---|---|---|
| Price | $6.21 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.2K | ★ 20.2K |
| Earning Date | 09-09-2025 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $1.48 |
| 52 Week High | $13.33 | $12.97 |
| Indicator | CURX | PLSM |
|---|---|---|
| Relative Strength Index (RSI) | 66.52 | 31.39 |
| Support Level | $4.02 | N/A |
| Resistance Level | $7.00 | $2.64 |
| Average True Range (ATR) | 0.43 | 0.15 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 100.00 | 31.22 |
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.